UNSPSC 51323107: Lodazecar

This classification denotes an anti-lipidemic agent with the molecular formula C22H24BrClN4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4D9016A00, chemically known as 1-(1,1-bis(hydroxymethyl)ethyl)-3-((s)-6-bromo-5-(o-chlorophenyl)-2,3-dihydro-1,3-dimethyl-2-oxo-1h-1,4-benzodiazepin-7-yl)urea but generally known as lodazecar, which bears US NIH Compound Identifier 65657. European Medicines Agency schedules Lodazecar in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08548MIG.

UNSPSC 51323107 Lodazecar is a Commodity code that encompasses advanced life support and emergency medications supplied to fire rescue, emergency medical services, and state health agencies. State and local governments procure these pharmaceutical products through sealed bids and cooperative purchasing arrangements, typically requiring vendors to meet FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act standards, and OSHA Safety Data Sheet documentation. Issuing bodies include city fire and rescue departments, state health agencies, and multistate cooperative purchasing alliances that aggregate demand across dozens of participating jurisdictions. The City of Tampa Fire Rescue and the Texas Health and Human Services Commission represent recent activity in this space, with additional volume channeled through cooperative vehicles such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP).

Recent opportunities reflect two procurement patterns. The City of Tampa issued an IFB (Solicitation 26P00188) in April 2026 for sealed bids on four specific advanced life support medication line items—Labetalol HCI, Epinephrine, Adenosine, and Diltiazem—with an estimated contract value of $40,000.00, a one-year term with two optional one-year renewals, and a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota MMCAP issued an RFP (S1070000015802) due March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), effective July 1, 2026, with price competitiveness weighted at 75 percent of evaluation and a two-year initial term. The Texas Health and Human Services Commission posted an RFI in April 2026 to assess vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling potential expansion of procurement models. Activity concentrates in the South (Florida, Texas) and Upper Midwest (Minnesota, with Oregon participation through MMCAP), with sealed-bid and cooperative purchasing vehicles predominating over individual state solicitations.